Welgus Howard G., DIR, reported an open-market or private sale at Arcutis Biotherapeutics, Inc. involving 10000.000000 shares for an estimated $146714.00. Reported holdings after the transaction were 151944.000000 shares. The stored filing text includes a detected 10b5-1 reference.
Stored Form 4 columns with their raw values
Badges describe filing facts only — not predictions.
Compact filing score computed from stored Form 4 facts. Version v1.
This filing is broadly neutral on the filing-only scale. The Form 4 facts do not strongly tilt positive or negative.
Form 4 relationship flags and nearby filing context
No officer title
The transaction reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted on March 5, 2024, by the Reporting Person, with a plan end date of May 30, 2025.
The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $14.16 to $15.11, inclusive. The Reporting Person hereby
undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respec…
price within the range set forth in this footnote.
0 other filings
0 recent txs